Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study

被引：0
|
作者：
Yang, James Chih-Hsin
Lee, Dae Ho
Lee, Jong-Seok
Fan, Yun
De Marinis, Filippo
Okamoto, Isamu
Inoue, Takako
Cid, Jeronimo Rafael Rodriguez
Zhang, Li
Yang, Cheng-Ta
Jimenez, Emmanuel De la Mora
Zhou, Jianying
Perol, Maurice
Lee, Hyeong
Lee, Ki Hyeong
Vicente, David
Ichihara, Eiki
Riely, Gregory J.
Luo, Yiwen
Bhagwati, Niyati Sanat
Lu, Shun
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[3] Asan Med Ctr, Seoul, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[5] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[6] Ist Europeo Oncol, Milan, Italy
[7] Kyushu Univ, Grad Sch Med Sci, Fukuoka, Japan
[8] Osaka Int Canc Inst, Osaka, Japan
[9] Med Sur Hosp, Ctr Oncol, Mexico City, Mexico
[10] Peking Union Med Coll Hosp, Beijing, Peoples R China
[11] Chang Gung Mem Hosp, Taoyuan, Taiwan
[12] Inst Jalisciense Cancerol, Guadalajara, Mexico
[13] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[14] Ctr Leon Berard, Lyon, France
[15] Chungbuk Natl Univ Hosp, Cheongju, South Korea
[16] Hosp Univ Virgen Macarena, Seville, Spain
[17] Okayama Univ Hosp, Okayama, Japan
[18] Mem Sloan Kettering Canc Ctr, New York, NY USA
[19] Merck & Co Inc, Rahway, NJ USA
[20] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9000
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
    Yang, James Chih-Hsin
    Lee, Dae Ho
    Lee, Jong-Seok
    Fan, Yun
    de Marinis, Filippo
    Okamoto, Isamu
    Inoue, Takako
    Cid, Jeronimo Rafael Rodriguez
    Zhang, Li
    Yang, Cheng-Ta
    Jimenez, Emmanuel De La Mora
    Zhou, Jianying
    Perol, Maurice
    Lee, Ki Hyeong
    Vicente, David
    Ichihara, Eiki
    Riely, Gregory J.
    Luo, Yiwen
    Bhagwati, Niyati Sanat
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA9000 - LBA9000
  • [2] Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor-Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer
    Yang, James Chih-Hsin
    Lee, Dae Ho
    Lee, Jong-Seok
    Fan, Yun
    de Marinis, Filippo
    Iwama, Eiji
    Inoue, Takako
    Rodriguez-Cid, Jeronimo
    Zhang, Li
    Yang, Cheng-Ta
    Jimenez, Emmanuel de la Mora
    Zhou, Jianying
    Perol, Maurice
    Lee, Ki Hyeong
    Vicente, David
    Ichihara, Eiki
    Riely, Gregory J.
    Luo, Yiwen
    Chirovsky, Diana
    Pietanza, M. Catherine
    Bhagwati, Niyati
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (34)
  • [3] Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789
    Riely, G.
    Hui, R.
    Carbone, D.
    Park, K.
    Carrigan, M.
    Xu, X.
    Dang, T.
    Yang, J. Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S494 - S494
  • [4] A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naive patients with advanced NSCLC.
    Lisberg, Aaron Elliott
    Cummings, Amy Lauren
    Goldman, Jonathan Wade
    Bornazyan, Krikor
    Reese, Nicholas Dean
    Wang, Tina
    Coluzzi, Paul
    Ledezma, Blanca A.
    Mendenhall, Melody A.
    Jones, Benjamin
    Madrigal, John
    Carroll, James M.
    Gukasyan, Jaklin
    Williams, Tawny
    Sauer, Lauren
    Wells, Courtney L.
    Hardy, Ariana R.
    Linares, Paulina J.
    Adame, Carlos R.
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC
    Lisberg, A.
    Cummings, A.
    Goldman, J. W.
    Bornazyan, K.
    Reese, N.
    Wang, T.
    Coluzzi, P.
    Ledezma, B.
    Mendenhall, M.
    Hunt, J.
    Wolf, B.
    Jones, B.
    Madrigal, J.
    Horton, J.
    Spiegel, M.
    Carroll, J.
    Gukasyan, J.
    Williams, T.
    Sauer, L.
    Wells, C.
    Hardy, A.
    Linares, P.
    Lim, C.
    Ma, L.
    Adame, C.
    Garon, Edward B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1138 - 1145
  • [6] A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naive Patients with Advanced NSCLC
    Lisberg, A.
    Hunt, J.
    Reese, N.
    Wang, T.
    Coluzzi, P.
    Spiegel, M.
    Bornazyan, K.
    Carroll, J.
    Madrigal, J.
    Ledezma, B.
    Mendenhall, M.
    Bui, J.
    Lu, H.
    Cummings, A.
    Noor, Z.
    Goldman, J. W.
    Garon, E.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1805 - S1805
  • [7] Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
    Wu, Shang-Gin
    Ho, Chao-Chi
    Yang, James Chih-Hsin
    Yu, Shu-Han
    Lin, Yen-Feng
    Lin, Shu-Chin
    Liao, Bin-Chi
    Yang, Ching-Yao
    Lin, Yen-Ting
    Yu, Chong-Jen
    Chuang, Ya-Ting
    Liao, Wei-Yu
    Yap, Kah Yi
    Kou, Weng Si
    Shih, Jin-Yuan
    CLINICAL AND TRANSLATIONAL MEDICINE, 2025, 15 (01):
  • [8] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Lam, Wei-Sen
    Le, Xiuning
    Eisert, Anna
    Himpe, Ulrike
    De Bondt, Charlotte
    Mazieres, Julien
    Petrini, Iacopo
    Tho, Lye Mun
    Ahmad, Azura
    Chik, Yin Kwan Jeannie
    Chung, Wai
    Lee, Kirsty
    Yang, Tsung-Ying
    Hsia, Te-Chun
    Joshi, Kirti
    Young, Louise
    Berghoff, Karin
    Vlassak, Soetkin
    Karachaliou, Niki
    van der Wekken, Anthonie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 83 - 84
  • [9] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Ahmad, A. R.
    Tho, L. M.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T-Y.
    Le, X.
    Eisert, A. K.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Lam, W-S.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    Van der Wekken, A. J.
    Hsia, T-C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
  • [10] Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
    Le, X.
    Eisert, A.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Tho, L. M.
    Ahmad, A.
    Lam, W. -S.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T. -Y.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    v. d. Wekken, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S483 - S484
12345